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Diamond-Blackfan anemia (DBA), an inherited bone marrow failure syndrome characterized by anemia that usually presents before the
ﬁrst birthday or in early childhood, is associated with birth defects and an increased risk of cancer. Although anemia is the most prom-
inent feature of DBA, the disease is also characterized by growth retardation and congenital malformations, in particular craniofacial,
upper limb, heart, and urinary system defects that are present in ~30%–50% of patients. DBA has been associated with mutations in
seven ribosomal protein (RP) genes, RPS19, RPS24, RPS17, RPL35A, RPL5, RPL11, and RPS7, in about 43% of patients. To continue
our large-scale screen of RP genes in a DBA population, we sequenced 35 ribosomal protein genes, RPL15, RPL24, RPL29, RPL32,
RPL34, RPL9, RPL37, RPS14, RPS23, RPL10A, RPS10, RPS12, RPS18, RPL30, RPS20, RPL12, RPL7A, RPS6, RPL27A, RPLP2, RPS25, RPS3,
RPL41, RPL6, RPLP0, RPS26, RPL21, RPL36AL, RPS29, RPL4, RPLP1, RPL13, RPS15A, RPS2, and RPL38, in our DBA patient cohort of
117 probands. We identiﬁed three distinct mutations of RPS10 in ﬁve probands and nine distinct mutations of RPS26 in 12 probands.
Pre-rRNA analysis in lymphoblastoid cells from patients bearing mutations in RPS10 and RPS26 showed elevated levels of 18S-E pre-
rRNA. This accumulation is consistent with the phenotype observed in HeLa cells after knockdown of RPS10 or RPS26 expression
with siRNAs, which indicates that mutations in the RPS10 and RPS26 genes in DBA patients affect the function of the proteins in
rRNA processing.Diamond-Blackfan anemia (DBA) (MIM 105650) is an
inherited bone marrow failure syndrome characterized by
anemia that usually presents during infancy or early child-
hood.1 Red cell aplasia is the most prominent feature of
DBA; however, the disease is also characterized by growth
retardation and congenital malformations, in particular
craniofacial, upper limb, heart, and urinary system defects
that are present in ~30%–50% of patients.2–4 In addition
to anemia and birth defects, the disease is associated
with predisposition to cancer, in particular acute myeloid
leukemia (AML) and osteogenic sarcoma.5,6 DBA is a clini-
cally heterogeneous disease: laboratory ﬁndings such as
increased mean corpuscular volume (MCV), elevated
erythrocyte adenosine deaminase activity (eADA), and
hemoglobin F are observed in a majority but not in all
DBA patients.7–9 Furthermore, within affected families,
some individuals may exhibit mild or absent anemia
with only subtle indications of erythroid abnormalities
such as macrocytosis, elevated eADA, and/or hemoglobin
F. The incidence of DBA is estimated to be between
1:100,000 and 1:200,000 live births9 or 5–7 per million
live births,2,10,11 which remains consistent across ethnic-
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222 The American Journal of Human Genetics 86, 222–228, Februarypatients are familial cases, with disease inherited in an
autosomal-dominant pattern; the remaining 55% of
patients are sporadic cases.3
DBA is genetically heterogeneous: heterozygous muta-
tions in four small subunit ribosomal protein (RP) genes,
RPS19 (MIM 603474), RPS24 (MIM 602412), RPS17 (MIM
180472), and RPS7 (MIM 612563), and in three large
subunit ribosomal protein genes, RPL35A (MIM 180468),
RPL5 (MIM 612561), and RPL11 (MIM 612562), have
been reported in about 43% of DBA patients, indicating
that DBA is a disorder of ribosomal biogenesis and/or func-
tion.12–16
Several studies showed that RPS19 protein plays an
important role in 18S rRNA maturation in yeast and in
human cells.17–20 Other studies demonstrated alterations
of pre-RNA processing and small or large ribosomal sub-
unit synthesis in human cells with RPS24, RPS7, RPL35A,
RPL5, and RPL11 deﬁciency.15,16,21 These observations
further indicate that DBA is a disorder of the ribosome.
Increased apoptosis has been demonstrated by Perdahl22
and also in hematopoietic cell lines and in bone marrow
cells with deﬁciency of RPS19 and RPL35A,15,23 and imbal-
ance of the p53 family proteins has been suggested asan Disease Research, Children’s Hospital Boston, Boston, MA 02115, USA;
er Children’s Hospital, Albert Einstein College of Medicine, New Hyde Park,
ulaire Eucaryote, Toulouse F-31000, France; 5CNRS, UMR 5099, Toulouse
n, Boston, MA 02115, USA; 7Harvard Medical School, Boston, MA 02115,
orcester, MA 01655, USA; 9Department of Cellular andMolecular Medicine,
ediatric Haematology and Oncology, Medical University ofWarsaw,Warsaw
rsity School of Medicine, Stanford, CA 94304, USA; 12Division of Pediatric
Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Genetics. All rights reserved.
12, 2010
Table 1. One Hundred and Seventeen Probands Studied for Mutations in 35 Ribosomal Protein Genes
All Studied
Probands
Sporadic
Cases
Familial
Cases
Probands Negative for Mutations in
Ribosomal Protein (RP) Genes S19, S24,
L35A, S17, S7, L5, L11, S15, S27A, and L36
Probands with Sequence Change in
RP Genes S19, S24, L5, L11, S15, and S27A
117 103 14 103 14a mechanism of abnormal embryogenesis and anemia in
zebraﬁsh upon perturbation of RPS19 expression.24 Fur-
thermore, the DBA phenotype in the mouse is ameliorated
by the knockdown of p53.25
Here we report the results of a large-scale screen of 35
additional RP genes in a cohort of 117 DBA probands.
Remarkably, we identiﬁed probable pathogenic mutations
in two of these genes, RPS10 (MIM 603632) and RPS26
(MIM 603701). In addition, we found a possible missense
mutation of RPL9 (MIM 603686) in one family.
One hundred and seventeen DBA families participated
in the study. The diagnosis of DBA in all probands and
their family members was based on normochromic, often
macrocytic, anemia; reticulocytopenia; a low number or
lack of erythroid precursors in bone marrow; and, in
some patients, congenital malformations and elevated
eADA. Among these families, 14 were multiplex families
and 103 comprised only one clinically affected individual.
One hundred and three probands were negative for muta-
tions in seven known DBA genes, RPS19, RPS24, RPL35A,
RPS17, RPS7, RPL5, and RPL11, and did not have any
sequence change in RPS15, RPS27A, and RPL36, previously
described as variants of unknown signiﬁcance.16 Twelve
probands were mutated in one of the known genes, three
with mutations in RPS19, one with RPS24, ﬁve with muta-
tions in RPL5, and three with RPS11 mutation. Two
probands had sequence changes in RPS15 and RPS27A,
previously described as variants of unknown signiﬁcance
(Table 1).16 Informed consent was obtained from all
patients and their family members participating in the
study under a protocol at Children’s Hospital Boston.
Genomic DNA was isolated from blood samples with
nucleic acid isolation system QuickGene-610L (AutoGen)
according to the manufacturer’s instructions. To continue
our large-scale screen of RP genes in a DBA population,
we ampliﬁed genomic DNA samples from 96 unrelated
DBA probands enrolled in the study by PCR and sequenced
formutations in 35 RP genes, RPL15, RPL24, RPL29, RPL32,
RPL34, RPL9, RPL37, RPS14, RPS23, RPL10A, RPS10, RPS12,
RPS18, RPL30, RPS20, RPL12, RPL7A, RPS6, RPL27A, RPLP2,
RPS25, RPS3, RPL41, RPL6, RPLP0, RPS26, RPL21, RPL36AL,
RPS29, RPL4, RPLP1, RPL13, RPS15A, RPS2, and RPL38
(chromosomes 3, 4, 5, 6, 8, 9, 11, 12, 14, 15, 16, and 17),
in our DBA patient cohort of 117 families (the majority
of the patient cohort is the same as in previous
studies).13,15,16 In total, we screened 64 RP genes, in addi-
tion to the 29 RP genes sequenced previously.13,15,16,26
Primers (see Table S1 available online) were designed
with Primer3 software to amplify the coding exons and
intron/exon boundaries of the above genes. PCR products,The Americabetween 200 and 600 base pairs long, were robotically
prepared with a Hamilton MicroLab STARplus (Hamilton
Robotics), puriﬁed with ExoSAP enzyme (USB), and
sequenced on both strands with an Applied Biosystems
3730 DNA Analyzer. The chromatograms were analyzed
with Sequencher software version 4.7 (Gene Codes).
When a sequence change was identiﬁed in a given gene,
we sequenced an additional 21 samples (for a total of 117
samples) from unrelated probands for mutations in this
gene. Duplicate, independent PCR products were
sequenced to conﬁrm the observed nucleotide changes in
the probands. DNA samples from at least 260 control
individuals, i.e., 520 chromosomes, were sequenced to
determine whether the observed sequence variations
were nonpathogenic variants. Subsequently, DNA samples
from available family members were sequenced to deter-
mine whether the mutation cosegregated with the DBA
phenotype within the pedigree.
Interestingly, we identiﬁed heterozygous sequence
changes in RPS10 in 5 of 117 probands. One sequence
change is a missense mutation 3G>A that changes Met1Ile
and eliminates the start codon. The next downstream start
codon is located at nucleotide position 61–63 (codon 21)
and is predicted to start translation of a truncated protein
of 144 amino acids. Another mutation is a c.260_261insC
causing a frameshift at codon 87 and a stop at codon 97.
Three other probands have a common nonsensemutation,
c.337C>T, causing Arg113 stop (Table 2). Proband P3 has
a de novo mutation, whereas SNP analysis of 14 polymor-
phisms spanning an ~20 kb region surrounding the RPS10
gene demonstrated that probands P3 and P4 do not
share the same background haplotype (data not shown)
(Table 2). All of these changes are unique (i.e., not previ-
ously described in the literature or databases), and two of
them were found in only a single kindred, whereas one
was seen in three unrelated families.
We also identiﬁed nine distinct mutations in 12 pro-
bands in RPS26 gene located on chromosome 12. Interest-
ingly, we found mutation of the ﬁrst codon, methionine
change to leucine, valine, or arginine, in six probands
and in two family members (Table 3), which suggests
that the translation-initiation codon may be a hot spot
in RPS26. These sequence changes eliminate a start codon;
the next downstream start codon is located at nucleotide
position 343–345. This is the last codon, codon 115, and
the protein is predicted to not be translated. Probands
P7–P10 share the same M1V mutation. Probands P7 and
P8 have de novo mutations, whereas SNP analysis of 15
polymorphisms spanning an ~20 kb region surrounding
the RPS26 gene demonstrated that probands P9 and P10n Journal of Human Genetics 86, 222–228, February 12, 2010 223
Table 2. Sequence Changes in RPS10 in DBA Patients
Proband’s ID
(Gender),
Inheritance
Family
Members
DNA
Mutation
Exon or
Intron
Predicted
Amino
Acid Change
Age at
Diagnosis
Malformation
Status
Response at
First Steroid
Therapy
Present
Therapy
P1 (M), sporadic - c.3G>A exon 1 Met1Ile NA NA NA NA
P2 (F), sporadic f – normal
sequence
c.260_261insC exon 3 frameshift
at codon 87;
stop at 97
2 mo none responsive steroid therapy
P3 (M), sporadic - c.337C>T exon 4 Arg113stop 7 mo none responsive RBC trx
P4 (F), sporadic - c.337C>T exon 4 Arg113stop 12 yrs none responsive steroid therapy
P5 (F), de novo f, m – normal
sequence
c.337C>T exon 4 Arg113stop birth webbed neck unresponsive RBC trx
The following abbreviations are used: P, proband; f, father; m, mother; ins, insertion; NA, not available; RBC trx, red blood cell transfusion.do not share the same background haplotype (data not
shown) (Table 3). Other identiﬁed mutations are two
missense mutations (c.97G>A changing Asp33Asn and
c.334T>C resulting in Met115Thr), insertion G in exon 2
causing frameshift at codon 11 and stop at codon 25,
and three donor splice-site mutations in introns 1 and 2.
All of these changes are also unique, and eight of them
were found in only a single kindred, whereas one was
seen in four apparently unrelated families (Table 3).
Parental DNA was available in two probands with RPS10
mutations and in seven with RPS26 mutations. De novo
sequence changes of RPS10 and RPS26 were identiﬁed in
one and ﬁve probands, respectively, with sporadic disease,
further supporting our belief that these sequence changes
are likely pathogenic mutations. In addition, six mutations
in RPS26 among 75 samples from DBA probands were
identiﬁed by a separate ongoing RP gene resequencing
project (unpublished data).
We also found a heterozygous missense mutation,
c.375G>C, resulting in Arg125Ser substitution in RPL9 in
one proband and his affected mother. None of the identi-
ﬁed sequence changes were found on the NCBI SNP lists,
and none were identiﬁed in at least 520 control chromo-
somes from a control population of similar, largely Euro-
pean origin.
Review of medical records of DBA probands and data
from the DBA Registry of North America (DBAR)4,6 re-
vealed that among four patients with RPS10 mutations
and available medical data, one had a physical malforma-
tion of a webbed neck and three patients were without
malformations, whereas among 11 RPS26mutated patients
whose clinical data were available, only three patients had
malformations. These physical abnormalities were similar
to those observed in other RP gene mutations (Table 2;
Table 3). One patient with RPS26 mutation has cleft lip
and cleft palate. Interestingly, to date this malformation
has only been found in DBA patients with RPL5 and
RPL11 mutations.16,27 Thus, the RPL26 gene is the third
DBA gene whose mutation is associated with clefting in
DBA. In general, physical malformations are present in
about 30%–50% of patients in the overall study cohort.2–4224 The American Journal of Human Genetics 86, 222–228, FebruaryAlthough the sample size is small, physical malformations
seem to be rare events in patients with RPS26 mutations.
Interestingly, 5 of 11 patients with RPS26 mutations
whose treatment data were available responded well to
the steroid treatment and six were unresponsive. Among
four patients with RPS10 mutations and available medical
data, three patients were responsive and one unresponsive
to steroid treatment. According to data fromDBAR, 79% of
DBA patients have been initially responsive to steroids,
17% unresponsive, and 4% were never treated with
steroids.4 At present, four RPS26-mutated patients are
dependent on red blood transfusions, three are steroid
dependent, two do not need any treatment, and two are
deceased (Table 3). Two RPS10-mutated patients are red-
blood-cell-transfusion dependent and two are dependent
on steroid treatment (Table 2).
The role of RPS10 and RPS26 in pre-rRNA processing was
assessed by knocking down expression of these proteins
with siRNAs in HeLa cells. Pre-rRNA processing analysis
was performed as previously described.21 Depletion of
both proteins led to decreased levels of 18S rRNA, indi-
cating that they are necessary for production of the small
subunit. Accordingly, RNA blot analysis of the pre-rRNAs
revealed that these proteins are both required for proper
processing of the pre-rRNA (Figure 1A). Depletion of
RPS26 led to the accumulation of 43S, 26S, and 18S-E
pre-rRNAs, which indicates defects in cleavages at both
ends of the 18S rRNA. Interestingly, knockdown of RPS10
expression yielded a very similar phenotype. This pheno-
type differed from what we observed previously upon
depletion of RPS19, RPS24, or RPS7, three other RPS
proteins mutated in DBA21 for which the processing was
blocked upstream of 18S-E pre-rRNA formation. Pre-rRNAs
were next detected by RNA blot analysis in RNAs extracted
from lymphoblastoid cells derived from patients with
mutations in RPS10 and RPS26 (Figure 1B). In the case of
the RPS26þ/mut patients, we compared their proﬁles to
those of unaffected relatives. Quantitative analysis by
phosphorimager indicated that four out of ﬁve patients
had elevated levels of 18S-E RNA when compared to their
relatives (Figures 1B and 1C). The remaining RPS26þ/mut12, 2010
Table 3. Sequence Changes in RPS26 in DBA Patients
Mutation
Type
Proband’s ID
(Gender),
Inheritance
Family
Members
DNA
Mutation
Exon or
Intron
Predicted
Amino
Acid
Change
Age at
Diagnosis
Malformation
Status
Response at
First Steroid
Therapy
Present
Therapy
Missense
mutation
P6 (M), de novo f, m, s –
normal
sequence
c.1A>T exon 1 Met1Leu NA none unresponsive RBC trx
- P7 (M), familial f, m –
normal
sequence
c.1A>G exon 1 Met1Val 2 mo none responsive steroid
therapy
- d of P7 c.1A>G exon 1 Met1Val 6 wks none unresponsive RBC trx
- P8 (M), de novo f, m –
normal
sequence
c.1A>G exon 1 Met1Val NA none unresponsive RBC trx
- P9 (M), familial - c.1A>G exon 1 Met1Val NA none responsive steroid
therapy
- d of P9 c.1A>G exon 1 Met1Val NA none responsive no therapy
- P10 (M), sporadic - c.1A>G exon 1 Met1Val 7 wks duplicated
pelvocalicon
on right
kidney
unresponsive RBC trx
- P11 (M), familial d – normal
sequence
c.1T>G exon 1 Met1Arg NA NA NA NA
- P12 (M), de novo f, m, s –
normal
sequence
c.97G>A exon 2 Asp33Asn 8 mo inguinal
hernia,
missing vas
deferens
(unilateral),
slightly
abnormal
epidymis,
pronounced
boney
prominence
of a cervical
spinous
process
unresponsive RBC trx
- P13 (M), de novo f, m, s –
normal
sequence
c.344T > C exon 4 Met115Thr 8 mo none responsive no therapy
Insertion P14 (F), sporadic - c.31_32insG exon 2 frameshift
at codon 11;
stop at 25
NA none unresponsive deceased
Splice-site
mutations
P15 (M), sporadic s – normal
sequence
donor splice
site IVS1þ1g>c
intron 1 - NA NA NA NA
- P16 (M) f, m, s, b –
normal
sequence
donor splice
site IVS1þ1g>a
intron 1 - NA none unresponsive RBC trx
- P17 (F), de novo f, m –
normal
sequence
donor splice
site IVS1þt>g
intron 2 - NA NA NA NA
The following abbreviations are used: P, proband; f, father; m, mother; d, daughter; s, sister; b, brother; ins, insertion; NA, not available; RBC trx, red blood cell
transfusion.patient instead showed a higher amount of 21S RNA,
a species just upstream the 18S-E RNA in the pre-rRNA
maturation pathway (Figures 1B and 1C, patient D).
Higher levels of 18S-E pre-rRNA were also detected in
RPS10þ/mut patients when compared to cells from unaf-
fected individuals (Figure 1B). Interestingly, this pheno-
type was not detected in an individual bearing a missenseThe Americamutation in RPS10 (Figure 1B, last lane). Higher levels of
18S-E pre-rRNA in RPS26þ/mut and RPS10þ/mut DBA
patients translated into high 18S-E/30S or 18S-E/21S
pre-RNA ratios (Figure 1D), whereas the 21S/30S ratio
remained in the same range as in controls, unlike in
RPS19þ/mut patient cells. The similarity of the pre-rRNA
pattern modiﬁcations in patient cells and in cells depletedn Journal of Human Genetics 86, 222–228, February 12, 2010 225
Figure 1. RNA Blot Analysis of the Effects of RPS10 and RPS26 Mutation on Pre-rRNA Processing
(A) HeLa cells were transfected with siRNAs to knock down RPS10 and RPS26 expression. RNAs extracted 48 hr posttransfection were
probed with oligonucleotides complementary to the 50 end of the ITS1 (50 ITS1), which detects the precursors to the 18S rRNA or to
the mature 18S and 28S rRNAs. Transfected cells show similar phenotypes with high levels of 43S, 26S, and 18S-E RNA, together
with low levels of 18S rRNA. Similar results were obtained with two independent siRNAs for each gene.
(B) Total RNAs from lymphoblastoid cells derived from DBA patients (Pt) and unaffected relatives were analyzed as in (A). Controls (Ct)
correspond to cells from unaffected individuals unrelated to patients. RNAs from patients mutated in RPS19 are also shown for compar-
ison. The last lane on the right corresponds to an individual bearing a missense change in RPS10, most likely a rare normal variant.
(C) Phosphorimager analysis of the 18S-E and 21S pre-rRNA levels in RPS26þ/mut patients shows that four out of ﬁve patients have
elevated levels of 18S-E rRNA when compared to their unaffected relatives. In each lane, measurements were normalized to the amount
of 28S rRNA and divided by the mean of the corresponding value in the three controls.
(D) Relative abundance of the 18S RNA precursors was quantiﬁed by phosphorimaging in DBA patients mutated in RPS10, RPS26, and
RPS19. Controls in this panel correspond to all the unaffected individuals shown in (B), both patient relatives and unrelated persons.of the corresponding ribosomal proteins strongly suggests
that the mutations in RPS10 and RPS26 identiﬁed in DBA
patients alter the function of ribosomal proteins in ribo-
some biogenesis, as shown before for other ribosomal
protein genes affected in DBA.
In summary, we found that mutations in RPS10 and
RPS26 are present in about 4.8% and 11.6% of our DBA
proband cohort, respectively. After correcting for the fact
that our study population was prescreened for RPS19,
RPS24, RPL35A, RPS17, RPL5, RPL11, and RPS7 mutations,
we estimate that RPS10 and RPS26 mutations are present
in about 2.6% and 6.4% of the overall DBA population.
The RPS10 gene is located on chromosome 6 and contains
six exons, with the start codon in exon 2. RPS10 encodes
a 165-amino-acid-long RPS10 protein, a component of
the 40S ribosomal subunit. In the present work, we identi-
ﬁed three sequence changes in RPS10 in ﬁve DBA
probands. In addition, we found one missense change,
c.71A>G, resulting in Lys24Arg in the patient with trans-
fusion-dependent anemia and in her unaffected brother.226 The American Journal of Human Genetics 86, 222–228, FebruaryAlthough this sequence change was not found in 285
control individuals, we strongly suspect that it may be
a rare normal variant because there is no phenotype in
the pre-RNAmaturation assay in the sample of the brother
carrying the sequence change (Figure 1B, last lane).
Because the substituted amino acid is also basic, we
hypothesize that this change affects only mildly the over-
all RPS10 conformation and/or function.
We also identiﬁed nine distinct mutations in the RPS26
gene in 12 patients. The RPS26 gene is located on chromo-
some 12 and contains four exons, with the start codon in
exon 1. This gene encodes a 115-amino-acid-long RPS26
protein, which is also a component of the 40S ribosomal
subunit. The translation-initiation codon may be a hot
spot for mutation in RPS26, because we found mutation
of the ﬁrst codon, methionine change to leucine, valine,
or arginine, in six probands and in two affected family
members (Table 3). One missense sequence change,
c.344T>C, resulting in substitution of methionine by thre-
onine at the last codon 115, may be a rare or private12, 2010
nonpathogenic genetic variant; therefore, the DNA sample
carrying this sequence change is currently being screened
for mutations in the remaining 15 RP genes.
The RPL9 gene is located on chromosome 4 and
comprises two isoforms, which contain seven and eight
exons, respectively. In the seven-exon-long isoform the
start codon is located in exon 1, and in the eight-exon-
long isoform the start codon is located in exon 2. Both
isoforms encode a 192-amino-acid-long RPL9 protein, a
component of the large ribosomal subunit. The only RPL9
missense change, c.375G>C, causingArg125Ser, was found
in one of the probands and his affected mother. Unlike for
mutations RPS10 and RPS26, lymphoblastoid cells estab-
lished from these persons do not display a pre-rRNA pro-
cessing defect similar to that observed upon knockdown
of RPL9 with siRNAs (data not shown). Our data do not
allow deﬁnitive determination of pathogenicity for this
mutation. Therefore, we consider this change to be a rare
variant of unknown signiﬁcance, and DNA samples
carrying these sequence changes are currently being
screened for mutations in the remaining 15 RP genes.
Thus, this report brings the total number of known DBA-
associated genes to nine and includes RPS19 (~25%),
RPS24 (~2%), RPS17 (~1%), RPL35A (~3.5%), RPL5
(~6.6%), RPL11 (~4.8%), RPS7 (~1%), RPS10 (~6.4%), and
RPS26 (~2.6%), in total accounting for approximately
~52.9% of patients with DBA. In addition, there were
four rare variants of unknown signiﬁcance identiﬁed in
RPS15, RPS27A, RPL36, and RPL9.12–16
Our data indicate that RPS10 and RPS26 contribute
differently to pre-rRNA processing when compared to
other RPS proteins involved in DBA, like RPS19 and
RPS24.18,21 It remains to be understood how mutations
in proteins having different functions in ribosome biogen-
esis all lead to the same disease. The most direct conse-
quence of these mutations is a defect in ribosome syn-
thesis. This may elicit a ribosomal stress response, to
which erythrocytic progenitors would be especially sensi-
tive at some stage of their differentiation. A defect of ribo-
some biogenesis may also alter regulation and efﬁcacy of
translation by affecting the rate of ribosome production
and ribosome quality. Such translation disorders could
disturb the synthesis timing of important regulators in
the erythrocyte differentiation pathway or impede high-
rate synthesis of globin. The effects of ribosomal protein
gene mutations could be further exacerbated in erythro-
cytic progenitors when compared to other cell lineages
because of the dramatic changes in gene expression
that result from the massive chromatin condensation
preceding nuclear extrusion. Generation of animal models
reproducing the mutations in RPS10 and RPS26 described
here could help to answer these questions.Supplemental Data
Supplemental Data include one table and can be found with this
article online at http://www.ajhg.org.The AmericaAcknowledgments
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